Tags : Ventilator-Associated

Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired

Vartika Singh June 4, 2019

Shots: The approval is based on P-III ASPECT-NP study results assessing Zerbaxa (3gm, IV every 8hrs.) vs meropenem (1gm, IV, every 8hrs.) in 726 patients with HABP/VABP on mechanical ventilation […]readmore

Tags : Ventilator-Associated

Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Ventilator-Associated

Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company